Trials / Unknown
UnknownNCT03152708
CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma
The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 62 (estimated)
- Sponsor
- CANbridge Life Sciences Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.
Conditions
Timeline
- Start date
- 2017-11-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-31
- First posted
- 2017-05-15
- Last updated
- 2017-09-21
Source: ClinicalTrials.gov record NCT03152708. Inclusion in this directory is not an endorsement.